spacer
The Healthcare Sales & Marketing Network celebrates 27 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  Aeterna Zentaris 

 HSMN NewsFeed - 27 Oct 2014
Aeterna Zentaris Announces Formal Implementation of its Sales Force In Support of Selling ASCEND's EstroGel(R)
Biopharmaceuticals Distribution
 HSMN NewsFeed - 5 Aug 2014
Aeterna Zentaris and ASCEND Therapeutics Sign Co-Promotion Agreement for U.S. Market
Biopharmaceuticals Distribution
 HSMN NewsFeed - 5 May 2014
Aeterna Zentaris Selects Charleston, S.C. as New Location for its North American Business and Global Commercial Operations
Biopharmaceuticals
 HSMN NewsFeed - 3 Mar 2014
Vansen Pharma Inc. appoints new President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2014
Aeterna Zentaris Appoints Dr. Richard Sachse as Chief Scientific Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Apr 2013
David A. Dodd Appointed President & Chief Executive Officer of Aeterna Zentaris Inc.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Jul 2010
Aeterna Zentaris Announces Perifosine Has Received Orphan-Drug Designation for the Treatment of Neuroblastoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 May 2010
Aeterna Zentaris: FDA Approves Investigational New Drug (IND) Application for Doxorubicin Targeted Conjugate Compound, AEZS-108, in Bladder Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 8 Apr 2010
Aeterna Zentaris Announces Initiation of Phase 3 Registration Trial with Perifosine in Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 5 Apr 2010
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Refractory Advanced Colorectal Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Mar 2010
AEterna Zentaris Receives Positive Opinion for Orphan Medicinal Product Designation for Perifosine for the Treatment of Multiple Myeloma from the Committee for Orphan Medicinal Products of the European Medicines Agency
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 18 Dec 2009
Aeterna Zentaris Announces Termination of Agreement with sanofi-aventis U.S. for the Development, Commercialization and Licensing of Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 7 Dec 2009
AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 2 Dec 2009
AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 2 Dec 2009
Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 16 Sep 2009
Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 17 Aug 2009
AEterna Zentaris Announces Results from Two Phase 3 Studies with Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 17 Jun 2009
Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System
Devices Monitoring Licensing Endocrinology
 HSMN NewsFeed - 6 Mar 2009
Sanofi-aventis and AEterna Zentaris Sign Agreement in the U.S.
Biopharmaceuticals Licensing Urology
 HSMN NewsFeed - 6 Mar 2009
AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Licensing Urology
 HSMN NewsFeed - 2 Dec 2008
Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Aug 2008
AEterna Zentaris Announces Appointment of Prof. Jurgen Engel, Ph.D. as New President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 4 Aug 2008
David J. Mazzo, Ph.D., Joins Regado Biosciences as President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Apr 2008
AEterna Zentaris Announces Changes to its Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Mar 2008
Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
 HSMN NewsFeed - 3 Mar 2008
AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
Biopharmaceutical Acquisitions
 HSMN NewsFeed - 29 Feb 2008
AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Aug 2007
AEterna Zentaris completes management team with the appointment of Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Jun 2007
Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstrom's Macroglobulinemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2007
Ozarelix Phase 2 Data in Benign Prostatic Hypertrophy Presented at Annual Meeting of American Urological Association
Biopharmaceuticals Urology
 HSMN NewsFeed - 8 May 2007
AEterna Zentaris Regains Exclusive Worldwide (ex-Japan) Rights from Solvay for Cetrorelix in Endometriosis Indication
Biopharmaceuticals
 HSMN NewsFeed - 7 May 2007
AEterna Zentaris Bolsters Management Team with Two Key Positions Named
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Apr 2007
AEterna Zentaris Reports First Patients Treated with Cetrorelix for Phase 3 Program in BPH
Biopharmacetuicals Urology
 HSMN NewsFeed - 26 Mar 2007
AEterna Zentaris Announces Appointment of New President and CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 19 Mar 2007
Spectrum Pharmaceuticals Bolsters Ozarelix Team with Addition of In-House Urology Expert Bela S. Denes, MD, FACS
Biopharmaceuticals Urology Personnel
 HSMN NewsFeed - 25 Jan 2007
Spectrum Pharmaceuticals Initiates Phase 2b Trial for Ozarelix in Patients with Benign Prostate Hypertrophy
Biopharmaceuticals Urology
 HSMN NewsFeed - 8 Jan 2007
AEterna Zentaris Initiates First Study of Phase 3 Program with Cetrorelix in BPH - 600 Patient Trial Conducted in the United States and Canada
Biopharmaceuticals Urology
 HSMN NewsFeed - 3 Jan 2007
Spectrum Pharmaceuticals Announces FDA's Acceptance of Ozarelix IND and Approval of Phase 2b Protocol in BPH (Benign Prostate Hypertrophy)
Biopharmaceuticals Urology
 HSMN NewsFeed - 28 Dec 2006
The Multiple Myeloma Research Consortium (MMRC) and Keryx Biopharmaceuticals Commence Multi-Center Combination Study for the Treatment of Multiple Myeloma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 3 Oct 2006
Spectrum Pharmaceuticals Announces Positive Phase 2 Data with Ozarelix in Patients with Benign Prostatic Hypertrophy
Biopharmaceuticals Urology
 HSMN NewsFeed - 3 Oct 2006
AEterna Zentaris Announces Positive Phase 2 Results for Ozarelix in Benign Prostatic Hyperplasia
Biopharmaceuticals Urology
Return to NewsFeed  

 Additional items found! 32

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 32 additional stories matching:
Aeterna Zentaris
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.